Therapeutic Advances in Psychopharmacology最新文献

{"title":"Ketamine alters the aperiodic EEG exponent in major depression: implications for cortical E/I balance and treatment prediction.","authors":"Yujuan Liu, Xiaorong Liu, Sebastian Olbrich, Chong-Leong Lao, Haoyun Zhang, Martin Brunovsky, Cheng-Teng Ip","doi":"10.1177/20451253261462240","DOIUrl":"10.1177/20451253261462240","url":null,"abstract":"<p><strong>Background: </strong>Ketamine has emerged as a promising rapid-acting antidepressant for treatment-resistant depression (TRD), yet its mechanisms of action and reliable biomarkers of treatment response remain poorly understood. Recent evidence suggests that the aperiodic exponent (1/f slope) of electroencephalography (EEG) power spectra reflects cortical excitation-inhibition balance (EIB), offering a potential non-invasive marker of treatment outcomes.</p><p><strong>Objective: </strong>Our study investigated whether subanesthetic ketamine modulates the EEG aperiodic exponent in patients with major depressive disorder (MDD), most of whom met criteria for TRD. We also examined whether pretreatment aperiodic exponent predicts antidepressant response.</p><p><strong>Design: </strong>A placebo-controlled, single-blind, one-arm, fixed-sequence design without randomization trial of intravenous ketamine infusion in patients with MDD.</p><p><strong>Method: </strong>Twenty-four MDD patients underwent both placebo and ketamine (0.54 mg/kg over 30 min) infusions. Resting-state EEG was recorded pre-, start-, end-, and 24 h post-infusion. Aperiodic exponent (1-40 Hz) was extracted using spectral parameterization. Depressive symptoms were assessed using the Montgomery-Åsberg Depression Rating Scale, with responders defined as ⩾33% symptom reduction 24 h post-infusion.</p><p><strong>Result: </strong>Meta-analysis revealed substantial heterogeneity in ketamine's effect on aperiodic exponents. In our cohort, ketamine significantly reduced the aperiodic exponent across the scalp. Notably, responders exhibited higher pretreatment occipital aperiodic exponents than non-responders. A steeper pretreatment 1/f slope in the occipital region predicted better treatment outcomes.</p><p><strong>Conclusion: </strong>Subanesthetic ketamine alters cortical aperiodic dynamics in MDD, potentially reflecting EIB modulation. The EEG aperiodic exponent, particularly in occipital regions, may serve as a useful biomarker for predicting antidepressant response to ketamine. However, our meta-analysis underscores the complexity and variability of the EEG aperiodic exponent. Future large-scale, multimodal studies are needed to validate and expand on these findings.</p><p><strong>Trial registration: </strong>EudraCT Number: 2013-000952-17 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000952-17/CZ).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261462240"},"PeriodicalIF":5.0,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148391627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-centred education for ketamine and esketamine therapies in mood disorders.","authors":"Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek","doi":"10.1177/20451253261456405","DOIUrl":"10.1177/20451253261456405","url":null,"abstract":"<p><p>Treatment-resistant depression (TRD) and bipolar depression (TRBD) are severe, heterogeneous mood disorders associated with substantial functional impairment, elevated suicide risk and persistent unmet treatment needs. While pharmacological and psychological interventions continue to advance, many patients experience delayed, partial or unsustained benefit, underscoring the need for therapies with novel mechanisms and rapid onset of action. Ketamine and esketamine have emerged as distinctive treatments in this context, demonstrating rapid antidepressant and anti-suicidal effects, yet differing fundamentally from conventional antidepressants in their acute subjective effects, physiological profile, delivery models and misuse potential. This narrative review synthesizes evidence from regulatory guidance, clinical trials, observational studies and qualitative research to identify key patient information needs and propose practical psychoeducational strategies. Core elements include explanations of indications, mechanisms and treatment algorithms; guidance on visit preparation, scheduling and monitoring; management of acute adverse effects; counselling on suicidality and substance misuse; and tailored considerations for special populations, including older adults, women of reproductive potential and medically complex patients. Drawing on this synthesis, the review proposes a patient-centred framework for ketamine and esketamine psychoeducation, outlining key informational domains and practical tools that can be embedded within clinical services, and identifies priorities for future research aimed at optimizing patient experience and supporting the responsible integration of ketamine-based therapies into mood disorder care.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261456405"},"PeriodicalIF":5.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148362596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Readability of informed consent forms from ClinicalTrials.gov in ketamine clinical trials for mental health conditions: a cross-sectional analysis.","authors":"Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała","doi":"10.1177/20451253261456385","DOIUrl":"10.1177/20451253261456385","url":null,"abstract":"<p><strong>Background: </strong>Ensuring participants understand informed consent forms (ICFs) is a core ethical requirement of clinical research, particularly in psychiatry, where cognitive and affective symptoms can compromise decisional capacity. As ketamine-based interventions are increasingly studied for mental health conditions, the readability of consent materials in these trials warrants systematic evaluation.</p><p><strong>Objectives: </strong>To assess the readability and linguistic complexity of ICFs from ClinicalTrials.gov used in ketamine clinical trials for mental health conditions.</p><p><strong>Design: </strong>Cross-sectional analysis.</p><p><strong>Methods: </strong>We conducted a cross-sectional analysis of English-language ICFs posted on ClinicalTrials.gov for interventional ketamine clinical trials involving mental health conditions. All documents were converted to plain text and standardised for text-based analysis. Readability and linguistic complexity were assessed using established indices, including the Flesch-Kincaid Grade Level, Gunning Fog Index, Flesch Reading Ease Score, and Fry Readability Graph. Document length and estimated silent reading time were also calculated. Descriptive statistics summarised the findings.</p><p><strong>Results: </strong>Fourteen ketamine clinical trials met the inclusion criteria. ICFs ranged from 1681 to 8637 words (mean: 5031; median: 4622), with sentence counts from 129 to 503. Estimated silent reading times ranged from 7.0 to 36.0 min (mean: 21.4; median: 19.5). Flesch-Kincaid Grade Level scores ranged from 5.7 to 11.5 (mean: 9.8), with 13 of 14 documents above grade 8. Gunning Fog Index values ranged from 7.7 to 13.8 (mean: 11.7). Flesch Reading Ease Scores ranged from 41.3 to 73.9 (mean: 52.8). Fry Readability scores ranged from grade 6 to grade 13.</p><p><strong>Conclusion: </strong>Thirteen of fourteen ketamine mental health trial consent forms on ClinicalTrials.gov exceeded recommended readability thresholds. Sponsors and ethics committees should require consent materials to meet an eighth-grade reading level, verified by a documented readability assessment before approval, to support informed participation in psychiatric research.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261456385"},"PeriodicalIF":5.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13319791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148369887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel.","authors":"Jaden Brandt, Nicole Lamberson, Jolene Bressi, Alexis Ritvo, Janice Curle, Josef Witt-Doerring, Marjorie DeWert, Steven Wright, Mark Horowitz","doi":"10.1177/20451253261457547","DOIUrl":"10.1177/20451253261457547","url":null,"abstract":"<p><strong>Background: </strong>Benzodiazepine receptor agonists (BZRA) are frequently tapered because of risk of dependence and hazards of use in ageing. Standard tapering protocols may fail or result in harm from improper utilization of pharmacologic principles, lack of recognition of withdrawal and/or failures in shared decision-making.</p><p><strong>Objective: </strong>The aim of this work was to derive principles from experts to optimize deprescribing success while minimizing withdrawal among patients who use BZRA medication long-term.</p><p><strong>Design: </strong>Modified Delphi consensus study among experts from two not-for-profit organizations dedicated to BZRA use issues.</p><p><strong>Methods: </strong>Three stages of anonymized voting were conducted among clinical experts and patient representatives. An 80% agreement ('agree' or 'strongly agree' on a five item Likert-type scale) was required for consensus. Recommendations which failed to reach initial consensus, were modified from feedback and downgraded to 'moderate' (>80% agreement) or 'weak' consensus (50%-80% agreement) in the subsequent rounds.</p><p><strong>Results: </strong>A total of 35 of 48 invitees participated (73% response rate) which included seven family physicians, nine psychiatrists, five pharmacists, six patient advocates, two nurse practitioners, two licensed clinical social workers, two health service policy researchers, a physician assistant and a psychotherapist. A total of 31 of 35 participants were from the United States, with the remaining representatives from Canada, the UK and Ireland. Strong consensus was achieved for attaining informed consent prior to deprescribing (recommendation 1), using a flexible and gradual tapering approach (recommendation 2) characterized by shared decision-making (recommendation 3) with hyperbolic dose reductions (recommendation 4) facilitated via novel preparation techniques or compounded pharmaceutical formulations (recommendation 7). Reversion to previous doses may occur if necessary to reduce the incidence of withdrawal (recommendation 6). Strong consensus was also reached for adjunctive psychosocial interventions (recommendation 8) and/or peer-support resources (recommendation 9). Moderate and weak consensus was achieved, respectively, for step-wise conversion to a longer-acting BZRA (recommendation 5) and the avoidance of adjunctive non-BZRA pharmacotherapy (recommendation 10).</p><p><strong>Conclusion: </strong>This consensus guidance document for primary care providers, mental health clinicians and long-term users of BZRA outlines ten principles/recommendations intended for improving deprescribing outcomes with an emphasis on minimizing withdrawal risk.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261457547"},"PeriodicalIF":5.0,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13254137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cariprazine augmentation for negative symptoms of schizophrenia: a prospective analysis and literature review.","authors":"Ewa Okon-Rocha, David Taylor","doi":"10.1177/20451253261456389","DOIUrl":"10.1177/20451253261456389","url":null,"abstract":"<p><p>Cariprazine is effective in a number of conditions and has shown efficacy in the treatment of negative symptoms. Data on its use as an adjunct to other antipsychotics is growing. To evaluate the effectiveness of add-on cariprazine in patients with predominant negative symptoms, we assessed a series of patients prescribed adjunctive cariprazine using the Schedule for the Assessment of Negative Symptoms (SANS). Patients had few positive symptoms, but negative symptoms were considered to have a major effect on functioning. SANS scores were calculated at baseline, 12 weeks and 24 weeks. We compared median scores using the Wilcoxon signed-rank test. Ten consecutive patients were evaluated. Median baseline SANS score was 87 (IQR 32), 66 (IQR 23) at week 12 (<i>p</i> = 0.002 vs baseline) and 57 (IQR 33) at week 24 (<i>p</i> = 0.006 vs baseline). At Week 12, 70% of the patients were still prescribed the initial starting dose of 1.5 mg daily, and at Week 24, 30% of the patients remained on the 1.5 mg/day dose. Adjunctive cariprazine was effective in the treatment of residual negative symptoms in people with minimal positive symptoms.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261456389"},"PeriodicalIF":5.0,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect.","authors":"Xiaoqian Lan, Hongyan Zhuang, Pengfei Li","doi":"10.1177/20451253261450772","DOIUrl":"10.1177/20451253261450772","url":null,"abstract":"<p><strong>Background: </strong>The potential of aripiprazole to reverse amisulpride-induced hyperprolactinemia has yet to be established.</p><p><strong>Objectives: </strong>To investigate whether adjunctive aripiprazole treatment can reverse amisulpride-induced prolactin (PRL) elevation.</p><p><strong>Design: </strong>This study was a single-arm retrospective cohort study.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of medical records from patients treated with amisulpride at a tertiary specialized psychiatric hospital, between June 1, 2022, and December 31, 2025, who subsequently received adjunctive aripiprazole. Data were collected via the electronic medical record system. A paired <i>t</i>-test was used to compare PRL values before (⩽7 days, PRL1) and after (⩾7 days, PRL2) aripiprazole initiation.</p><p><strong>Results: </strong>The difference between PRL1 and PRL2 was not statistically significant (mean difference = 4.115 ng/ml, 95% CI (-5.121, 13.351) ng/ml, SD = 15.284, <i>p</i> = 0.351, Cohen's <i>d</i> = 0.269, 95% CI for <i>d</i> (-0.290, 0.818)). Stratified analyses by sex and diagnosis yielded results consistent with the main analysis across subgroups (<i>p</i> > 0.05). None of the leave-one-out analyses altered the study's conclusions (all <i>p</i>-values > 0.05), indicating that the results were not driven by any single extreme value.</p><p><strong>Conclusion: </strong>In individuals with amisulpride-related hyperprolactinemia, this retrospective study suggests that adjunctive aripiprazole has an insignificant therapeutic effect in reversing PRL elevation. Therefore, until more comprehensive research evidence becomes available, a cautious approach should be taken in clinical practice regarding the use of adjunctive aripiprazole to reverse amisulpride-induced PRL elevation.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261450772"},"PeriodicalIF":5.0,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148138933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early suicidal ideation change and suicidality-associated emergency department utilization after ketamine or esketamine treatment in treatment-resistant depression.","authors":"Liliana Patarroyo-Rodriguez, Vanessa K Pazdernik, Jennifer L Vande Voort, Simon Kung, Balwinder Singh","doi":"10.1177/20451253261450747","DOIUrl":"10.1177/20451253261450747","url":null,"abstract":"<p><strong>Background: </strong>Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear.</p><p><strong>Objectives: </strong>To examine whether early improvements in SI, measured using item 12 of the Quick Inventory of Depressive Symptomatology - Self Reported (QIDS-SR), following (es)ketamine treatment are associated with SAED visits over 6 months.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>Individuals with TRD who had available data on SI measured using the QIDS-SR during the acute phase, as well as data on SAED visits over 6 months, were included. Participants were classified based on changes in SI as resolved, partially improved, or unchanged/worsened using the QIDS-SR item 12 during acute treatment (up to six intravenous (IV) or eight intranasal (IN) treatments) and were followed for SAED visits.</p><p><strong>Results: </strong>Among 96 patients with SI data, 73 (76%) had baseline SI. Following acute-phase treatment, 36 (49%) achieved SI resolution, 14 (19%) partially improved, and 23 (32%) were unchanged/worsened. During the 6-month follow-up, 8 (11%) had post-acute SAED visits. While not statistically significant, patients with resolved SI had lower odds of post-acute ED visits (OR = 0.16, <i>p</i> = 0.12). Kaplan-Meier estimates of SAED visit-free survival across three SI change groups trended toward significance (<i>p</i> = 0.066), suggesting lower cumulative healthcare (ED) utilization in more favorable change groups. Secondary analysis among 57 patients who received IV ketamine and had baseline SI showed that, after two infusions, 33 (47.2%) demonstrated a reduction in SI. Early SI improvement (⩾50% reduction in SI) was associated with a lower likelihood of any post-treatment SAED visit at 6 months after adjusting for pre-treatment SAED (OR = 0.17, 95% CI: 0.02-0.98, <i>p</i> = 0.047), corresponding to numbers needed to treat of 4.3.</p><p><strong>Conclusion: </strong>Early SI changes may have prognostic implications, though larger studies are needed to confirm clinical significance.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261450747"},"PeriodicalIF":5.0,"publicationDate":"2026-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13198639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.","authors":"Kristian Beichmann, Polina Catzeflis, Helena D Aicher, Federico Seragnoli, Abigail Calder, Adam Amrani, Gregor Hasler","doi":"10.1177/20451253261448745","DOIUrl":"10.1177/20451253261448745","url":null,"abstract":"<p><strong>Background: </strong>The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-<i>N</i>-methamphetamine (MDMA).</p><p><strong>Objectives: </strong>The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH).</p><p><strong>Design: </strong>Swiss PAT practices were examined using an anonymous survey of physicians providing PAT. Questions included physicians' backgrounds, training, therapeutic orientation, treatment protocols, patient characteristics, and perceived benefits.</p><p><strong>Methods: </strong>Participants were recruited from PAT professional associations and the research team network. Forty-one physicians providing PAT under FOPH exemptions contributed to the survey.</p><p><strong>Results: </strong>Respondents used PAT primarily for depression, anxiety, post-traumatic stress disorder (PTSD), and chronic pain. Most physicians practiced in private practices, private outpatient clinics or shared practices (82%), with a minority in hospitals (18%). The most reported labels when providing PAT were body-oriented (61%), psychodynamic (59%), and eclectic (54%) approaches. Respondents provided PAT using psilocybin (85%), MDMA (71%), and LSD (65.9%). Choice of first substance was linked to diagnosis, with physicians preferring psilocybin for depression (54%) and substance use disorder (46%) and MDMA for PTSD (86%) and anxiety disorders (54%). A total of 90% reported always playing music during psychedelic sessions. Loss of orientation in time and space, feeling too cold, anxiety, and nausea where the most frequent adverse effects of PAT. 95% had emergency medication available, on average used during 2.4% of sessions. Challenges included legal constraints, high patient expectations, and financial barriers. Group therapy was common, with 9% reporting providing only group sessions, 42% providing both individual and group settings, and 47% providing only individual sessions. Only 9% reported never using co-sitters.</p><p><strong>Conclusion: </strong>This study offers valuable insights into the methods and experiences of physicians providing PAT in a legal clinical context, giving insight into the considerable variety of clinical methods. Cultural and regulatory differences may limit generalizability.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261448745"},"PeriodicalIF":5.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study\".","authors":"","doi":"10.1177/20451253261452482","DOIUrl":"https://doi.org/10.1177/20451253261452482","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/20451253261437597.].</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261452482"},"PeriodicalIF":4.0,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191112/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148017431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient views on paliperidone palmitate 3-monthly: a cross-sectional questionnaire in UK community mental health teams.","authors":"Ivana Clark, Siobhan Gee, David Taylor","doi":"10.1177/20451253261450788","DOIUrl":"10.1177/20451253261450788","url":null,"abstract":"<p><strong>Background: </strong>Naturalistic studies examining paliperidone palmitate 3-monthly (PP3M) long-acting injection have proven PP3M to be a safe and effective maintenance treatment for patients with schizophrenia.</p><p><strong>Objectives: </strong>The aim of this study is to explore patients' views and experiences with PP3M.</p><p><strong>Design: </strong>This was a cross-sectional, non-interventional, one-time questionnaire which was designed by pharmacists in collaboration with clinicians experienced in the use of long-acting antipsychotic injections.</p><p><strong>Methods: </strong>Eligible patients were adults currently prescribed PP3M who were attending their routine long-acting injection administration appointment at their community mental health team (CMHT).</p><p><strong>Results: </strong>Of 172 patients who were due PP3M during the study period, 68 (39.5%) completed the questionnaire. Of these, 31.3% found PP3M extremely helpful, 43.3% found it very helpful, 17.9% somewhat helpful, 3% slightly helpful and 4.5% not helpful at all. The majority of respondents (83.8%) preferred PP3M over PP1M, with convenience being cited as the main reason for preference (62.9%). The majority reported mild (35.4%) or no injection pain (30.8%) and no new side effects on PP3M (80.6%). For those experiencing side effects, they were largely not considered troubling (24.6%). CMHT contact remained unchanged since switching to PP3M (56.9%). In-person appointments were considered important (33.8%) or very important (35.4%). Most patients either had no preference (40.3%) or were opposed to having a monthly appointment (32.3%). When asked about preferred injection frequency, patients overwhelmingly selected the 3-monthly (62.5%) or 6-monthly option (35.9%).</p><p><strong>Conclusion: </strong>Patients generally reported high levels of satisfaction with PP3M and perceived the treatment to be helpful and well-tolerated, with most expressing a preference for PP3M compared with a 1-monthly injection.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261450788"},"PeriodicalIF":5.0,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13187388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147988518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}